Google, Lendlease axe plans for $15 billion development in Bay Area
Alphabet’s Google has scrapped a development deal to build $15 billion worth of homes, offices and retail space in California’s Silicon Valley. Google and
Palomar Holdings, Inc. (PLMR) Q3 2023 Earnings Call Transcript
Palomar Holdings, Inc. (NASDAQ:PLMR) Q3 2023 Earnings Conference Call November 2, 2023 12:00 PM ET Company Participants Chris Uchida – CFO McDonald Armstrong –
McCormick wants the US to divest from China. As a hedge fund manager, he oversaw investments in Chinese companies
In Republican David McCormick’s second bid for US Senate in Pennsylvania, he has rebranded himself as a Trumpian-hardliner on China, sounding the warning bells
Stellar Bancorp Vice Chairman George Martinez Won’t Stand for Re-Election
By Denny Jacob Stellar Bancorp board member and vice chairman George Martinez notified the company he won’t stand for re-election at its 2024 annual
Real estate stocks lead European shares to biggest weekly gain since March
By Ankika Biswas and Bansari Mayur Kamdar (Reuters) -Europe’s benchmark index posted its biggest weekly gain since March on Friday, supported by interest rate-sensitive
Two of the world’s most powerful tech execs come from the same Taiwanese family
Jensen Huang and Lisa Su have a lot in common. The chief executives of Nvidia (NVDA) and AMD (AMD) aren’t just two of the
SES SA (SGBAF) Q3 2023 Earnings Call Transcript
SES SA (OTCPK:SGBAF) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET Company Participants Richard Whiteing – VP & Head, IR Ruy
Watch Chris Christie scold audience after being booed for his opposition to Trump
Watch Chris Christie scold audience after being booed for his opposition to Trump Republican presidential candidate and former New Jersey Gov. Chris Christie scolds
Forget U.S. stocks for now. Invest here instead, says Bridgewater’s co–investment chief
As a co–chief investment officer of Bridgewater Associates, the world’s biggest hedge-fund firm, Karen Karniol-Tambour scours global markets for good investment opportunities. She’s increasingly
Mirati Gets MHRA Approval for Krazati to Treat Non-Small Cell Lung Cancer Patients
By Stephen Nakrosis Mirati Therapeutics said on Friday the U.K.’s Medicines and Healthcare Products Regulatory Agency gave conditional marketing approval for Krazati to treat
Most Read
